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AUTHORIZES BONDS TO CONTINUE FUNDING STEM CELL AND
OTHER MEDICAL RESEARCH. INITIATIVE STATUTE.
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December 17, 2019
Initiative 19-0022 (Amdt. #1)
The Attorney General of California has prepared the following title and summary of the chief
purpose and points of the proposed measure:
AUTHORIZES BONDS TO CONTINUE FUNDING STEM CELL AND OTHER
MEDICAL RESEARCH. INITIATIVE STATUTE. Authorizes $5.5 billion in state general
obligation bonds to fund grants from the California Institute of Regenerative Medicine to
educational, non-profit, and private entities for: (1) stem cell and other medical research, therapy
development, and therapy delivery; (2) medical training; and (3) construction of research
facilities. Dedicates $1.5 billion to fund research and therapy for Alzheimer’s, Parkinson’s,
stroke, epilepsy, and other brain and central nervous system diseases and conditions. Limits
bond issuance to $540 million annually. Appropriates money from General Fund to repay bond
debt, but postpones repayment for first five years. Summary of estimate by Legislative Analyst
and Director of Finance of fiscal impact on state and local governments: State costs of $7.8
billion to pay off principal ($5.5 billion) and interest ($2.3 billion) on the bonds. Associated
average annual debt payments of about $310 million for 25 years. The costs could be
higher or lower than these estimates depending on factors such as the interest rate and the
period of time over which the bonds are repaid. The state General Fund would pay most of
the costs, with a relatively small amount of interest repaid by bond proceeds. (19-0022A1.)
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125290. 72. Expand Alpha Stem Cell Clinic Proqram and Establish Community Care Centers of
Excellence

Proqram.

(a) The institute

shall

expand

the Alpha

Stem

Cell Clinic Proqram

and establish

the Community

Care

Centers of Excellence Proqram to fund the establishment of centers of excellence at which clinical trials
are conducted and treatments and cures made available for all patients. The qoal of the Community
Cr:ireCenters of Excellence Proqram is to expand the capacity of the Alpha Stem Cell Clinic Proqram to
promote access to human clinical trials and the accessibility of treatments and cures arisinq from
institute-funded research for patients in California by establishinq qeoqrr:iphically diverse centers of
excellence

to conduct

clinical

trir:ils and to seek to make

the resultinq

treatments

and cures

broadly

available to California patients.
(b) The institute shall prioritize the fundinq of applications for Community Care Centers of Excellence that
enhance the qeoqraphic distribution of Community Care Centers of Excellence across the state,
considerinq the location of the Alpha Stem Cell Clinics, to promote patient access. The institute shall
prioritize applications for Alpha Stem Cell Clinics and Community Care Centers of Excellence that offer
matchinq funds and/or verified in-kind support, consistent with the hiqhest medical standards, as
established by the Governinq Board of the institute.
(c) Applications for Alpha Stem Cell Clinic and Community Care Centers of Excellence qrants shall be
required to include a plan for enhancinq access to clinical trials for California patients and makinq
treatments and cures that arise from institute-funded research more widely available to California
patients, includinq addressinq how the applicant will support the ancillary hospital and access costs of
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patients participatinq

in clinical trials to enhance access to trials for California patients, reqardless of

their

and qeoqraphical

economic

means

location.

(d) Alpha Stem Cell Clinic and Community Care Centers of Excellence awards shall be made pursuant to
the procedures set forth in Article /, Chapter 3, Division 106, Part 5 of the Health and Safety Code.
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proqrams shall be to: (1) ensure that California has the workforce necessary to move new discoveries
from the research staqe to the clinic; (2) accelerate the accessibility of treatments and cures, and to
make treatments

and cures arisinq from institute-funded

prepare California underqraduates

research available to California patients; (3)

and masteYs students for careers in stem cell research and other vital

research opportunities and in the development and delivery of treatments and cures; and (4) to support
qraduate students, post-doctoral students, and medical students, includinq but not limited to interns,
residents, and qraduate fellows who work in the fields of stem cell and other vital research opportunities
and in the development and delivery of treatments

and cures, with fellowships.
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and create employment
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in

students and medical school

students, includinq but not limited to interns, residents, and qraduate fellows, enqaqed in stem cell
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(B) The institute

may establish

a proqram

to empower

fellows

to work in Alpha Stem Cell Clinics

and Community

Care Centers of Excellence as part of their participation

in the fellowship

proqram.

(b) Traininq

and fellowship

proqram

awards shall be made pursuant

to the procedures

set forth

in Article /, Chapter 3, Division 106, Part 5 of the Health and Safety Code.
SEC. 6. Section

125290.

74.

125290.74

Shared

is added

Research

to the

Laboratory

Health

and Safety

Code

to read

as follows:

Proqram.

(a) The institute shall re-establish a Shared Research Labomtory Proqram to provide fundirHl to academic
and nonprofit research institutions
culture materials, and instruction

in California for specialized instrumentation,

a supply of cell lines,

and traininq in research methods and techniques.

Research Laboratory qrants shall be required to offer use of the research laboratory
conductinq research at the awardee institution
research institutions,

and to offer instruction

the awardee institution

Awardees of Shared
to investiqators

and to provide a reasonable access plan for neiqhborinq

and traininq opportunities

to students and investiqators

and to provide a reasonable access plan for neiqhborinq

research institutions.

(b) The institute shall prioritize the fundinq of applications that enhance the qeoqraphic distribution
Shared Research Laboratories

at

of

across the state and applications that offer matchinq funds or verified in-

kind support.

(c) Shared Research Laboratory Proqram awards shall be made pursuant

to the procedures

set forth

in Article /, Chapter 3, Division 106, Part 5 of the Health and Safety Code.
SEC, 7. Section

125290.75.

125290.75

Treatments

is added

to the

Health

and Cures Accessibility

and Safety

andAffordability

Code

to read

as follows:

Workinq Group.

(a) Membership

The Treatments and Cures Accessibility and Affordability

Workinq Group shall have 1 7 members

nominated by the Chair or Vice Chair and approved by the Board as follows:
(1) Five members of the ICOC (the "Governinq
the appointments

Board"), with at least two of those members drawn from

made pursuant to paraqraphs (3), (4), (5) or (6) of subdivision (a) of Section

125290.20.

(2) An individual

qualifications,
neqotiations

who

has

private sector experience

and the process for reimbursement,

in innovative

therapy

medical

coveraqe

terms,

includinq, if possible, experience with coveraqe

with private insurers, health manaqement

orqanizations,

or corporate self-insurance health
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(3) An expert or a hiqhly knowledqeable
qualifications,
Medicare

individual with experience in federal therapy coveraqe,

and process for reimbursement,

and Medicaid

includinq, if possible, experience with the Centers for

Services.

(4) An expert or a hiqhly knowledqeable

individual with experience in California's public insurance

proqram (Covered California), coveraqe, qualifications,

and the process for reimbursement

of innovative

therapies.

(5) Two representatives
that

are treatinq

from hospitals in California that are participatinq

patients

(6) A representative

with

Druq Administration-approved

from o philanthropic

trial access and affordability,
(7) Two representatives

orqanization

stem

or with access to, and the affordability

with

experience

in advisinq

therapies.

of, innovative therapies.

who have technical expertise or experience

and the process for reimbursement

care economist,

cell or qenetic

who has experience assistinq patients with clinical

from patient advocacy orqanizations

in coveraqe, qualifications,
(8) A health

Federal

in stem cell clinical trir:ils or

of innovative therapies.

or neqotiatinq

with private

insurers,

qovernment

insurers, or corporate self-insurance proqrams on coveraqe for innovr:itive therapies or humr:in trials,
includinq experience in assistinq hospitals and clinics in coverinq financial qaps in coveraqe of the direct
and indirect costs of innovr:itive therapies.
(9) A patient naviqator

with traininq and experience helpinq patients obtain financial support from

private insurers, public support, or nonprofit support, and helpinq patients obtain socir:il service support
to facilitate

their participation

qualification

in Federal Druq Administration-approved

human trials or their

for access and financial assistance for innovative therapies.

(IO) The chairperson and vice chairperson of the Governinq Board.
(b) Functions
The Treatments and Cures Accessibility and Affordability

Workinq Group shall have the followinq

functions:
(1) To examine, develop, and assist with the implementation
accessibility and affordability

of treatments

of financial models to enhance the

and cures arisinq from institute-funded

Californir:ins, and to enhance access to clinical trials, includinq reimbursement
qualified costs to help achieve the objective that reimbursement

alternatives for patient-

covers patient expenses, includinq but

not limited to, medical expenses, lodqinq, meals, and travel for research participants
careqive

research for

and their

rs.
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(2) To recommend to the Governinq Board policies and proqrams to help Californians obtain access to
human clinical trials and to make treatments
to California patients throuqhout

and cures arisinq from institute-funded

research available

California.

(3) To recommend to the Governinq Board policies and proqrams to help Californians afford to
participate

in human clinical trials and to make treatments

and cures arisinq from institute-funded

research r:iffordable to California patients, reqardless of their financial means.
(4) To work with the Alpha Stem Cell Clinics and Community Care Centers of Excellence and other
California healthcare institutions,
proqrams, and foundations,
affordability

of treatments

and healthcare payors, includinq private insurers, qovernment

to develop model proqrams and coveraqe models to promote the access and
and cures arisinq from institute-funded

research for California patients,

reqardless of their financial means, or the disease, iniury, or health condition from which they suffer.
(5) To advise the Governinq Board reqardinq the coveraqe criteria and the process for reimbursement
innovative therapies and cures arisinq from institute-funded
throuqh publicly or privately-funded

of

research and made available to patients

proqrams in California with the qoal of expandinq access and

affordability.
SEC. 8. Section

125290.76.

125290.76

Advisory

is added

to the

Health

and Safety

Code to read

as follows:

Task Forces.

(a) Membership

The Chair and the President may appoint one or more advisory task forces to provide expert quidance to
address specific obiectives in areas under the institute's
financial, and technical matters.

iurisdiction,

includinq scientific, policy, ethical,

The Chair and President shall each appoint r:in equal number of

members with expertise in the area or areas for which advice is souqht, includinq at least one member
who has a patient

advocate

perspective.

(b) Functions
The advisory task forces shall advise the Board throuqh the Chair and the President, reqardinq scientific,
policy, financial, ethical, and technical matters under the institute's

iurisdiction.

(c) Operr:itions

(1) The advisory task forces shall be advisory only and their operations shall be subiect to the
requirements
shall

meet

applicable to workinq qroups pursuant to Section 125290.50,

in public

when

they

vote

on policy

provided that the task forces

recommendations.
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(2) Members of the advisory task forces shall be subiect to the conflict of interest requirements
applicable to members of the workinq qroups, provided that the advisory task forces shall not review,
comment upon, or have iurisdiction
SEC. 9. Section

125290.20.

125290.20

of the

ICOC Membership;

over any individual qrant or loan approval.

Health

and Safety

Appointments;

Code

Terms

is hereby

amended

to read

as follows:

of Office.

(a) ICOC Membership
The ICOC shall

have 2-!;)35 members,

appointed

as follows:

(1) The Chancellors of the University of California at San Francisco, Davis, San Diego, Los AngelesL
Irvine,

and Riverside

shall

each appoint

an executive

officer

from

his or her campus.

In addition,

the

Chancellor of the University of California at San Francisco shall also appoint a faculty member,
physician/scientist,
qeoqraphic

researcher, or executive officer from the UCSFFresno/Clovis campus to promote

diversity

(2) The Governor,
executive

the

officer

Lieutenant

from

(A) A California
paragraph

and access.

university,

(1), that

opportunities,

excluding

categories:

the

seven

success

development,
research

the Treasurer

three

has demonstrated

therapy

(i) A nationally-ranked
four

Governor,

the following

campuses

and leadership

or therapy

hospital

and the Controller

delivery,

and medical

of the

school;

University

in stem

and that

shall each

appoint

of California

cell research,

an

described

other

vital

in

research

has:

this criteria

will apply

to only two

of the

appointments.

(ii) A recent proven history of administering

scientific and/or medical research grants and contracts in an

average annual range exceeding SIOO million.
(iii) A ranking

within

oflife-science

the

patents

past five years

or that

in the top 10 United

has research

or clinical

faculty

States

universities

who

are members

with

the

of the

highest

National

number
Academy

of Sciences.

(iv) For purposes of this cateqory, the Governor may appoint an executive officer from the California
State

University

system

who

has an advanced

(B) A California

non-profit

California,

has demonstrated

that

opportunities,

therapy

(i) A nationally-ranked
National

Academy

(ii) A proven

academic

and research
success

development,
research

deqree

institution

and leadership

or therapy

hospital

in bioloqical

delivery,

or that

that
in stem

and that

has research

sciences.
is not a part of the
cell research,

other

University
vital

of

research

has:

or clinical

faculty

who

are members

of the

of Sciences.

history

in the

last five years

of managing

a research

budget

in the

life sciences

exceeding

S20 million annually.
(C) A California
therapies

life-science

or therapy

delivery

commercial
with

entity

pluripotent

that

is not actively

or progenitor

stem

engaged

in researching

cells or qenetic

medical

or developing
treatments,
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has a background

in implementing

includinq

conductinq

human

Institute

at the time

of appointment.

clinical

qualifications
with a succcsr,ful
lieu of an executive officer.

l or developinq
trials,

and that

has not been awarded,

A board member

history

experimental

of developing

of such entity
innovative

medical
or applied

for, funding

who qenerally

medical

therapies

therapies,

meets

by the

the same

may be appointed

in

(D) Only one member shall be appointed from a single university, institution, or entity for the purposes
of paragraph

(2). The executive

science commercial
to an executive

entity

officer

(3) The Governor,
from

among

officer

who

is appointed

of the entity

the Lieutenant

California

of a California

university,

as a member,

a nonprofit

may from

or to the dean of the medical

Governor,

representatives

the Treasurer,

of California

research

time to time delegate

school,

state,

or life

those

duties

if applicable.

and the Controller

regional,

institution

shall appoint

or national

members

disease advocacy

groups,

as follows:
(A) The Governor
groups:

shall appoint

spinal cord injury;

(B) The Lieutenant
advocacy
health

Governor

groups:

type

t-we three members,

one from

Alzheimer's

and mental

disease;

shall appoint

II diabetesy

three members,

multiple

sclerosis

(C) The Treasurer

shall appoint

and heart

two

shall appoint

two

and Parkinson"s

disease.

(4) The Speaker

of the Assembly

California

one from

or amyotrophic

regional,

(5) The President

members,

one from

advocacy

each of the following
lateral

each of the following

state,

one from

shall appoint

or national

pro Tempore

members,

sclerosis;

disease

and mental

(6) The Treasurer

mental

of the Senate

and Controller

stem cell or qenetic

a member
health

from

shall appoint

shall each r:ippoint

therapy

officer

chairperson.
chairperson

(i) Documented

a candidate

a member
HIV/AIDS

history

from

cancer

representatives

of a

conditions
among

disease

advocacy

group.

California

advocacy

group.

in clinical

trial manaqement

by the ICOC members.
and another

shall each be elected

of ICOC shall be full- or part-time

candidate

for a term

employees

Each
for vice

of six years.

of the institute

The

and shall

Criteria

in successful

stem cell research

development and/or therapy delivery

advocacy.

(ii) Experience

legislative

legislative

health

disease groups:

criteria:

Chairperson

with

California

a nurse with experience

for chairperson

and vice chairperson

and vice chairperson

meet the following
(A) Mandatory

type I

delivery.

shall nominate

The chairperson

among

disease or mental

chairperson and vice chairperson who shall be elected

constitutional

disease groups:

each of the following

representatives of a California regional, state, or national

medical

disease

conditions.

disease.

(D) The Controller

p 14

health

conditions.

diabetes

and/or

each of the following

state and federal
approvals

of standards

and/or

or other

processes

that

vital research

must include

opportunity

in t

some experience

with

funding.
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(iii) Qualified for appointment
(iv) Cannot

be concurrently

institutions

in California.

(B) Additional

Criteria

(i) Experience

with

(ii) Experience

the

chairperson,

the

legal

review

shall

among

satisfy

preferably

of proper

grant

or loan recipient

covering

executive

standards

governmental

or board

and procedures.
authority

for the exercise

of

financing.

(i), (iii), and (iv) of subparagraph

who

position).

powers.

in bond

clauses

individuals

(either

government

institutional

and experience

The vice chairperson
from

any prospective

or institutions

of establishing

or government

knowledge

be selected

agencies

process

with

agency

by or on leave from

for Consideration:

(iii) Legal experience

(iv) Direct

employed

governmental

with

government

pursuant to paragraph (31 (4), or (5) of subdivision (a).

have attributes

the criteria

(A).

and experience

not represented

by the

The vice chairperson

complementary

chairperson's

shall

to those

credentials

of the

and

experience.
(b) Appointment

of ICOC Members

(1) All appointments

shall

of the appointments

are not completed

operate
have

with

been

the

elect

days after

within

pursuant

Terms

eight-year

(2) If a vacancy
within

X

the

permitted
provided

date

or this

timeframe,
that

the

at least

act.

In the event

ICOC shall

60 percent

that

proceed

any

to

of the appointments

a term

members

shall continue

among

of the

the

and the Treasurer,
appointed

individuals

or if only

members

of the

one is

ICOC to

nominated

by the constitutional

(5)

of subdivision (a) shall

(a).

pursuant to paragraphs (1), (3), (4i ai

within

(3) When

from

a meeting

(7) of subdivision

unless

90 days to serve

(4) Notwithstandinq

shall convene

and all other

terms,

occurs

of this act, the Controller

of Office

terms,

of two

date

and vice chairperson

(1) The members appointed
maximum

40 days of the effective
within

are in place,

the effective

to paragraph

(c) ICOC Member

serve

that

45 days, the other

a chairperson

officers

appointments

within

made.

(2) Forty-five
available

be made

expires,

the
the

members

earlier

a term,

removed
the

appointing
until

pursuant

appointing

remainder

to serve

shall serve

six-year

terms.

to paraqraph

authority

shall

Members

shall serve

(5).

appoint

a replacement

member

of the term.
authority

their

shall

appoint

replacements

paraqraph (1), the appointinq

authority

a member

within

'W 90 days.

half of the membeYs current term by appointinq

ICOC

are appointed.

may replace

a member,

other

than

Chair or Vice Chair, who has served, as of the effective date of the Act addinq this paraqraph,
term. Such appointments

a

the

at least

a new member, who shall be eliqible to serve a full

shall be made within 90 days of the effective date of the Initiative addinq this

paraqraph.
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(5) The ICOC may, by a vote of sixty percent (60%) of a quorum, recommend the removal of a member by
the membeYs appointinq
nominatinq

authority,

authority,

or in the case of the chairperson and the vice chairperson, the

or nominatinq

authorities if more than one constitutional

officer nominated

the

person.The appointinq

authority, or nominatinq authority or authorities in the case of the chairperson
and vice chairperson, shall have the authority to remove the member, or chairperson or vice chr:iirperson,
respectively, upon receipt of the ICOC's recommendation.

If more than one constitutional

officer

nominated the chairperson or vice chairperson, each of them must aqree in order to remove the
chairperson or vice chairperson.
SEC.10. Section 125290.30 of the Health and Safety Code is hereby amended to read as follows:
125290.30.
(a) Annual

Public and Financial Accountability
Public

Standards.

Report

The institute shall issue an annual report to the public which sets forth its activities,
grants in progress, research accomplishments,
include, but not be limited to, the following:

and future program directions.

grants

awarded,

Each annual

report

the number and dollar amounts of research and facilities

grants; the grantees for the prior year; the institute's

administrative

expenses;

an assessment

availability of funding for stem cell research from sources other than the institute;

of the

a summary

of

research findings, including promising new research areas; an assessment of the relationship
the institute's
strategic

grants and the overall strategy of its research program;

research

(b) Independent

and financial

shall

and a report

of the

between
institute's

plans.

Financial Audit for Review by State Controller

The institute shall annually commission an independent

financial audit of its activities from a certified

public accounting firm, which shall be provided to the Controller, who shall review the audit and
annually issue a public report of that review.
(c) A performance

audit shall be commissioned

by the institute every three years beginning with the

audit for the 2010-11 fiscal year. The performance

audit, which may be performed by the Bureau

State Audits, shall examine the functions, operations,

management

procedures of the institute to assess whether the institute
effectiveness in the employment
accordance with government

systems,

is achieving economy,

of available resources. The performance

auditing standards, and shall include a review

complying with ICOC policies and procedures. The performance
review of scientific performance.

The first performance

and policies

of

and

efficiency,

and

audit shall be conducted
of whether the institute

audit shall not be required

in
is

to include

audit shall include, but not be limited

a

to, all of

the following:

(1) Policies and procedures for the issuance of contracts and grants and a review of a representative
sample of contracts, grants, and loans executed by the institute.
(2) Policies and procedures relating to the protection
associated with research funded or commissioned
(d) All administrative

costs of the audits

required

or treatment

ofintellectual

property rights

by the institute.
by subdivisions

(b) and (c) shall

be paid by the

institute.
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(e) Citizen's

Financial

Accountability

There shall be a Citizen's
committee

the Senate,
member

Financial

shall review

and the financial

the Speaker

institute's

practices

period.

The committee

report.

The ICOC shall provide
members

(f) Public Meeting

members

matters.

meeting,

shall evaluate

report

public

comments

shall provide

and with

funds for all costs associated

public

meetings

advocacy

appropriate

public

a public

on the
The

comment

summaries

with the per diem expenses

of

backgrounds

staff support.

a formal

audit,

pro Tempore

recommendations

shall provide

and include

annual

or patient

This

of that

the President

of the ICOC shall each appoint

notice,

ofthe

by the Controller.

and evaluation

the Treasurer,

The Controller
appropriate

and for publication

chaired

shall have medical

with

in its annua

of the

report.

Laws

(1) The ICOC shall hold at least twe
institute's

the Controller's

The committee

and performance.

shall hold a public

committee

audit,

Committee

and the Chairperson

Committee
financial

Oversight

The Controller,

of the Assembly,

of relevant

financial

committee

financial

of the institute.

of the committee.

Committee

Accountability

the annual

practices

and knowledge

Oversight

annual

meeting.

per year, one of which

The ICOC may hold additional

meetings

will be designated

as it determines

as the

are necessary

or

appropriate.
(2) The Bagley-Keene
1 of Division
otherwise

Open Meeting

3 of Title 2 of the Government

provided

meetings

Act, Article

in this section.

and shall adopt

9 (commencing

Section 11120)

Code, shall apply to all meetings

The ICOC shall award

all governance,

with

scientific,

all grants,

medical,

of Chapter

1 of Part

of the ICOC, except

loans, and contracts

and regulatory

standards

as

in public
in public

meetings.
(3) The ICOC may conduct
Section 11126

constitute

including,

information

involving

individuals

commercial

competitors

(D) Matters

concerning

only be taken

of personal

intellectual

to, any formula,

data, or compilation

who do not know

officers

by the Bagley-Keene
the ICOC may conduct

to patients

or medical

Open Meeting

Act, under

closed sessions

when

it

subjects,

the disclosure

of which

would

privacy.

property

or work

plan, pattern,

product,

whether

tool,

mechanism,

process,

ofinformation,

who are using it to fabricate,

involving

which

produce,

is not patented,

or compound

gives its user an opportunity

patentable

to obtain

or not,

compound,
which

an article

is known

of trade

a business

only

or a service

advantage

over

it or use it.

prepublication,

confidential

the appointment,

and employees.

Action

scientific

employment,

research

performance,

on compensation

or data.
compensation,

of the institute's

officers

or dismissal

of

and employees

shall

shall be deemed

to be

in open session.

(4) The meeting
a special

invasion

value and which

(C) Matters

institute

In addition,

relating

confidential

production

to certain
having

involving

but not limited

procedure,

Code.

as permitted

or discuss:

an unwarranted

(B) Matters

sessions

of the Government

meets to consider
(A) Matters

closed

meeting

required

by paragraph

for the purposes

(2) of subdivision

of Section 11125.4

(b) of Section 125290.20
of the Government

Code.
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(g) Public

Records

(1) The California
Division

Public

Records

Act, Article

7 of Title 1 of the Government

otherwise

provided

(2) Nothing

1 (commencing

Code,

shall

apply

with

Section

to all records

6250)

of Chapter

of the institute,

3.5 of

except

as

in this section.

in this

section

shall

be construed

to require

disclosure

of any records

that

are any of the

following:

(A) Personnel,
invasion

medical,

of personal

(B) Records

containing

patentable

or not,

compound,
known

or similar

or reflecting

including,

procedure,

having

advantage

individuals

commercial

over

competitors

(C) Prepublication

scientific

and proqress

member's

shall
votes

data,
who

of which

would

intellectual

constitute

property

to, any formula,
or compilation

are using

do not know

working

papers

plan,

an unwarranted

or work
pattern,

ofinformation,

it to fabricate,

and which

who

product,

process,

which

produce,

whether
tool,

mechanism,

is not patented,

or compound

gives its user an opportunity

which

an article

to obtain

is

of trade

a business

it or use it.

or research

(1) The institute

shall,

except

requirements

(commencing

with

in all meeting

and recusals

Bidding

of this

as provided

to the

10500)

in this

minutes,

on all action

as otherwise

applicable
Section

(3) The requirements
(4) Except

confidential

value

include,

(h) Competitive

bidding

disclosure

data,

includinq

but not limited

to applications

reports.

(3) The institute
board

the

but notlimited

production

only to certain

or a service

files,

privacy.

University

section

shall

section,

in this section,

Public

tallies

of California,

be governed

as set forth

2.1 of Part 2 of Division

not be applicable

the

of vote

and disclosure

of each

items.

provided

of Chapter

a summary

Contract

to grants
Code shall

by the competitive

in Article

2 of the

or loans

1

Public

Contract

approved

not apply

Code.

by the

to contracts

ICOC.

let by the

Institute.
(i) Conflicts

oflnterest

(1) The Political
apply

Reform

to the institute

Act, Title

and to the

9 (commencing
ICOC, except

with

Section

as provided

81000)

in this

of the Government

section

and in subdivision

Code,

shall

(e) of Section

125290.50.
(A) No member

of the

official

to influence

employer,

position

ICOC shall

but a member

make,

a decision
may participate

participate
to approve

in making,
or award

in a decision

or in any way
a grant,

to approve

loan,
or award

attempt

or contract
a grant,

to use his or her
to his or her
loan,

or contract

to
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an entity
(B) A member
an entity
family

in the same

of the

for the

suffers

field

as his or her employer.

ICOC may participate

purpose

of research

or in which

the

in a decision

involving

member

to approve

a disease

has an interest

from

or award

which

a grant,

a member

as a representative

loan,

or contract

to

or his or her

of a disease

advocacy

organization.

(2) Service

as a member

University

of California

orinimical

to the

of the

nonprofit

of the

both

(A) The grant,

loan,

member

the

(B) The member

intellectual
patents,

trials

with

intellectual

establish

the

standards

need to ensure

that

that

established
Fund,

pursuant

the

from

making,

that

from
medical

a decision

and loan

recipients

shall

and facilities

self-commercializing
below.

paragraph

sh,ill
Statts

United

(A) (i) A grantee

grant

rtctivcd

be deposited
Codt,
that

at a minimum,

recipients,

an invention

/\11 rcvcnucs

thc

include,

share

or technology

pursuant
in the

to this
General

by the

research

by law,

loan or contract.

the

be deposited

into

of patient-qualified
a requirement

that

paragraph

by the
property

an interest-bearinq

so deposited

account

and interest

thereon

and cures arisinq

means to purchase such

CIRM grantees,

revenue

from

and clinica

hindered

intellectual

from

costs for research participants.

that

of the

arises

to

to benefit

development,

unreasonably

through

the amount

be subject

the costs of providinq treatments

a fraction

ICOC or

or in any way

of California

therapy

is not

received
shall

of the

he or she represents.

awards

of the State

research to California patients who have insufficient

standards

to

as a

made

in making,

on the grant

for the purpose of offsettinq

(2) These

not be deemed

by any member

from institute-funded

or cure, includinq the reimbursement

a

ICOC member

or the entity

shr:ill be appropriated
treatment

shall

Service

of California

all grants

revenues

permitted

organization,

or contract

participating

basic research,

to this subdivision

and to the extent

member

the opportunity

All

loan,

to be provided

benefits

require

result

essential

agreements.

to any grant,

Paid to the State

balance

of the

of any system

such office.

are met:

to influence

that

that

and licenses

property

General

position

entity

duties

with,

or entity.

to services

or herself

Revenues

agreements

royalties,

agreements
in the

himself

and License

property

relates

or financially

to use his or her official
Royalties

not apply

conditions

directly

represents

fails to recuse

(1) The ICOC shall

the

or contract

institution,

Code shall

of the following

advocacy

commercial

to the

of either

of the

in conflict

or administration

vacation

of a disease

or inimical

of any system

incompatible,

of the faculty

automatic

or a life science

with,

organization,

of the Government

where

in the

or employee

institution,

or administration

to be inconsistent,

as a member

not result

in conflict
of that

of the faculty

be deemed

ICOC member
and shall

or employee
1090

by itself,

and research

the entity

(j) Patent

of the

incompatible,

representative

attempting

not,

ICOC by a representative

academic

ICOC except

ICOC by a member

of California

be inconsistent,

(3) Section

shall

duties

University

as a member

of the

they

research

or regulations

Fund for use consistent

receive

funded

adopted

other

than

from

licensing

by CIRM,
to implement

with

Scction

202(c)(7)

from

o research

loan
or

as set forth
this
of Title

35 of

if applic.:iblc.

licenses

an invention

or technology

that

arises

funded

by
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CIRM, reqardless of the number of qrants awarded to that research proqram, shall pay 25 percent of the
revenues it receives in excess of five hundred thousand dollars (S500,000), in the aggregate, to the
General Fund. The threshold amount of five hundred thousand dollars (5500,000) shall be adjusted
annually

by a multiple

Consumers,
Labor

of a fraction,

All Items

Statistics

(San Francisco-Oakland-San

of the

and the numerator

the denominator

United

States

of which

Consumer

Jose; 1982-84=100)

Department

of Labor

which is that index published

of

is the

as prepared

and published

for the

Price Index,

month

by the

for the month

in which

All Urban

Bureau

of

of October

the grantee

accepts

2009,

the

gra nt. For awards made on or after November 5, 2020, the threshold amount of five hundred thousand
dollars (5>500,000) shall be adiusted annually by a multiple of a fraction, the denominator of which is the
Consumer
Price Index, A// Urban Consumers,
A// Items (San Francisco-Oakland-San
lose; 1982-84=100)
as
prepared by the Bureau of Labor Statistics of the United States Department

of Labor and published for

the month of October 2020, and the numerator of which is that index published for the month in which
the qrantee

accepts

(ii) If funding

sources

technology,
funding

then

for the

and that

arises

from

shall

(ii) In addition

or technology

annual

Fund shall

shall

or grants

of the

required

that

is the

The rate

by clause

of funding

provided

of payback

an invention

of the

(i), the first

the

time

of CIRM

by all sources,

to three

of the research

royalty

Fund.

or technology

Fund equal

in support

from

or

due to the General

to the General

by the grantee

invention

The amount

from

by the grantee

of the

as follows:

percentage

results

pay an amount

received

development

by the total

numeral

received

product.

net revenue

to the

be calculated

be divided

a product

by CIRM shall

payment

contributed

by 25. That

self-commercializes
funded

to the

General

be multiplied

to the creation
of the

CIRM directly

to the

of the CIRM grant

contributed
percent

that

than

return

invention

research

amount

other

the

fraction

(B) (i) A grantee

total

the qrant.

that
times

the

that

shall be at a rate of 3

product.

that

net commercial

revenues

earned

by the grantee from the product exceed two hundred fifty million dollars (S250,000,000) in a calendar
year,

the grantee

amount

shall

of the grant

contributed

make

a one-time

or grants

to the creation

payment

awarded

of the

to the General

by CIRM to the grantee

Fund equal
in support

to three

of the

times

research

the total
that

product.

(iii) In addition to the payments required by clauses (i) and (iil the first time that net commercial
revenues earned by the grantee from the product exceed five hundred million
a calendar
three

year,

times

research

the total

that

to the

earned

(S500,000,000)

the invention

CIRM grant
that

or grants

contributed

grant

creation

from

year,

in excess

one-time

or grants
of the

the

awarded

hundred

or technology,
amounting

to more

to modify

than

(S500,000,000) in

dollars

to the General

by CIRM to the grantee

Fund equal

in support

to

of the

(il (ii), and (iii), the first time that net commercial
equal

shall

five

or exceed

five

pay the General

million

if the grantee

of the

payment

product.

product

the grantee

of five

have the authority

authority

an additional

required by clauses

payments

to the creation

(3) The ICOC shall
also have the

of the

by the grantee

revenue

make

to the

in a calendar

commercial
covering

shall

amount

contributed

(iv) In addition
revenues

the grantee

dollars
patented

million

hundred

Fund 1 percent

(S500,000,000)
its invention

dollars

million

for the

annually

of net

life of any patent

or technology

(S5,000,000)

dollars

in support

and received
of the

a

research

product.

to adopt
the formulas

regulations

to implement

specified

in subparagraphs

this subdivision.

The ICOC shall

(A) and (B) of paragraph

(2)
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through

regulations

either

in order

if the

to ensure

that

development

and the

that

of California

the State

result

from

basic

appropriate

to vote

essential

broad

delivery

medical

to patients,

modification

Legislature

of the formulas

a modification

but not limited

the

patents,

trials.

hindered,

royalties,

days before

in subparagraphs

or to ensure

and licenses

The ICOC shall notify

10 calendar

specified

is required

to, therapy

is not unreasonably

from

and clinical

of the

(1) that

including,

to benefit

development,

committees

to paragraph

research,

of therapies

therapy

and policy
on the

pursuant

has an opportunity

research,

fiscal

authority

ICOC determines

that

the

exercising

its

(A) and (B) of

paragraph (2). The amendments made to this subdivision (i) are not intended to affect the institute's
authority

to modify the provisions set forth in this subdivision (i) pursuant to this paraqraph,

but not limited to any modifications

includinq

that occurred prior to the effective date of the Initiative amendinq

this subdivision.
(k) Preference

for California

The ICOC shall establish
suppliers

to the

percent

extent

Suppliers

standards

of such purchases

(l) Additional

to ensure

reasonably
from

Accountability

California

grantees

in a good

faith

purchase
effort

goods

and services

to achieve

from

a goal of more

California

than

SO

suppliers.

Requirements

To assure strict accountability
research and treatment

that

possible,

and transparency, includinq riqorous conflict of interest rules, ethical

standards, and independent financial audits, every four years the ICOC shall

update, at its discretion, the standards relatinq to conflict of interest rules, ethical research and
treatment,

and independent

financial audits, to be qenerally aliqned with standards adopted by the

National Academy of Sciences to the extent that such standards are consistent with constitutional
statutory

requirements

SEC. 11.

Section

125290.35.

In order

to the institute.

of the

Health

and Scientific

and Safety

Accountability

Code

is hereby

amended

to read

as follows:

and medical

research,

Standards.

Standards

to avoid

alternative
out the

125290.35

Medical

(a) Medical

r:ipplicable

duplication

state
specific

or conflicts

programs,
controls

125300,

the

in technical

institute

and intent

125320,

will

of the

standards

develop

for scientific

its own

scientific

act, notwithstanding

125118,

125119,

and medical

subdivision

125119.3

cells,

or other

vital

committees,

and its grantees

of standards,

the

award

Standards
initially

shall

of grants

(b) The ICOC shall establish
(1) Informed

research

opportunities,

and 125119.5,

be governed

solely

and the conduct

standards

as follows:

informed

consent

except

Section

by the

provisions

of grants

awarded

standards

(b) of Section

125315.

stem

with

to carry

Scctions

or any other

future state laws or regulations dealing with the study and research of pluripotent
progenitor

and

current

or

cells and/or

The ICOC, its working

of this act in the establishment
pursuant

to this

act.

Consent
for obtaining

shall

be generally

the

based

of research

on the standards

in place

donors,

patients,

on January

or participants,

1, 2003,

for all research

which
funded

by
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National

Institutes

of Health,

with

modifications

to adapt

to the

mission

and objectives

of the

institute.
(2) Controls
Standards
the

on Research
for the

Institutional

on January

review
Review

1, 2003,

(3) Prohibition
Standards

Involving

Humans

of research
Board

with

involving

standards

modifications

human

subjects

which

by the

National

promulgated
to adapt

to the

mission

initially

shall

Institutes

and objectives

be generally
of Health

of the

based

on

and in effect

institute.

on Compensation

prohibiting

reimbursement

compensation

to research

donors

or participants,

while

permitting

of expenses.

(4) Permitted

Reimbursement

Standards permittinq

reimbursement

for expenses, which shall include but not be limited to medical

expenses and lodqinq, meals, and travel expenses for research participants

and careqivers in order to

ensure functional access to clinical trials. For purposes of this paraqraph, "careqivers"
members, friends, and professional careqivers providinq supportive care.

includes family

(4) (fl Patient Privacy Laws
Standards

to assure

compliance

with

state

and federal

patient

privacy

laws.

J,!d{fl Limitations on Payments for Cells
Standards
the

limiting

removal,

processing,

implantation
specifically
processes

%

payments

for the

disposal,

purchase

preservation,

or legal costs or other
including

any required

for royalties,

patent,

of stem
quality

administrative
payments

or licensing

cells or stem
control,

costs

for medical
fees or other

cell lines to reasonable

storage,

associated

with

or scientific
costs for

transplantation,
these

medical

technologies,
intellectual

payment

for

or
procedures

products,

and

or

property.

Time Limits for Obtaining Cells

Standards
initially

setting
be 8

a limit

on the time

to 12 days after

during

cell division

which

cells may be extracted

begins,

not counting

any time

from

blastocysts,

during

which

which
the

shall

blastocysts

and/or cells have been stored frozen.
(8) Standards for Genetic Medical Treatments and Research
Standards for research involvinq qenetic medical treatments

which shall, in the ICOC's discretion,

qenerally be based on the standards adopted by the National Academy of Sciences.
SEC. 12.

125290.40.

Section

125290.40

of the

Health

and Safety

Code

is hereby

amended

to read

as follows:

ICOC Functions.

The ICOC shall

perform

the following

functions:
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(a) Oversee

the

(b) Develop

annual

(c) Make

final

operations

decisions

trials

(d) Ensure

strategic

on research

research

standards

and financial

and grant

plans for the

awards

in California

institute.

across

the research

and

and delivery spectrum, from stem cell discovery research and early development to

and therapy

delivery.

the completion

(e) Issue public

institute.

and long-term

therapy development
clinical

of the

reports

of an annual
on the activities

financial

audit

of the

institute's

operations.

of the institute.

(f) Develop and implement proqrams to enhance patient access to affordable stem cell and related
treatments

and cures

intellectual

property

(q) Establish

throuqh
rights

and oversee

public

arising

hospitals

from

the institute's

and clinics

research

funded

research,

therapy

and
by the

policies

regarding

institute.

development,

and therapy

delivery

proqrams,

includinq but not limited to the Alpha Stem Cell Clinics and Community Care Centers of Excellence,
traininq and fellowship, and shared research laboratory proqrams.
(h) Establish and oversee the development

of policies and proqrams to help make treatments

r:ind cures

arisinq from institute-funded research availr:ible and affordable for California patients, throuqh
with healthcare providers,
research and therapy development institutions, businesses,

enqaqement

qovernmental aqencies, philanthropists, foundations, and patient advocacy qroups, and based on
recommendations made by the Treatments and Cures Accessibility and Affordability Workinq Group.
(-g){il Establish rules and guidelines for the operation of the ICOC and its working groups.
% {il Perform all other acts necessary or appropriate
jurisdiction

over

p JSelect
ffl

and

members of the working groups.

Adopt, amend, and rescind rules and regulations to carry out the purposes and provisions of this

chapter,

and to govern

and regulations
Code,

J,k4{

in the exercise of its power, authority,

the institute.

Title

shall

the

procedures

be adopted

2, Division

of the

ICOC.

in accordance

with

3, Part 1, Chapter

4.;>

3.5

Except

as provided

the Administrative

Sections

.143-74 11340

in subdivision
Procedure

(km),

these

rules

Act (Government

et seq.).

Notwithstanding

commencement

the Administrative Procedure Act (APA), and in order to facilitate the immediate
of research
covered
by this chapter, the ICOC may adopt interim regulations without

compliance

the

with

procedures

set

forth in the APA. The interim

regulations shall remain

in effect

for

270 days unless earlier superseded by regulations adopted pursuant to the APA. For purposes of
subdivision (l), requests for applications,
considered

proqram announcements,

and notices of award shall not be

requlations.

p (z;4Request the issuance of bonds from the California Stem Cell Research and Cures Finance
Committee

j

and loans from

the

Pooled

Money

Investment

Board.

{gl May annually modify its funding and finance programs to optimize the institute's

ability to
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achieve
years

the objective
of operation

that

its activities

without

jeopardizing

W {pl Notwithstanding
personal

property,

the

progress

for the State

of its core

Section 11005 of the Government

including,

used to supplement

be revenue-positive

but

annual

not limited

research

grant

to, gifts,
funding

of California

medical

Code, accept additional

royalties,

interest,

and the operations

during

and scientific

its first

research

revenue and real and

and appropriations
of the

five

program.

that

may be

institute.

(q) Subiect to the restrictions set forth in this article, develop conflict of interest standards, and at its
discretion, consult with the National Academy of Sciences and the Scientific and Medical Accountability
Standards Workinq Group, for the consideration of fundinq awards based on best practices established
by the National Academies of Sciences to prevent conflicts of interest in the award of research fundinq
and update those standards no less than every four years to be, at the ICOC's discretion, qenerally
aliqned with standards adopted by the National Academies of Sciences, subiect to the constitutional and
statutory

requirements

SEC. 13.

Section

125290.45.

applicable

125290.45

to the institute.

of the

Health

and Liability

(1) The institute

may sue and be sued.

(2) Based

upon

harmless

against
from

ICOC standards,

research

conducted

shall

(3) Given

the scientific,

11042

institute

any and all losses,

grantees

Section

Code

is hereby

amended

as follows:

ICOC Operations.

(a) Legal Actions

arising

and Safety

name

the institute

that

shall

damages,

by the grantee

medical,

and technical
Code,

the institute

or insure

including

attorneys'

fees,

grant, and/or, in the alternative,

and submit

of the

and hold the institute

or liabilities,

to the

insured
nature

the

requires

indemnify

expenses,

pursuant

as an additional

of the Government

ICOC determines

grantees

claims,

proof

issues facing

institute

is authorized

specialized

services

of such insurance.

the

to retain
not

ICOC, and notwithstanding
outside

provided

counsel

when

by the Attorney

the

General's

office.
(4) The institute

may enter

into

any contracts

or obligations

which

are authorized

or permitted

by law.

(b) Personnel
(1) The ICOC shall from

time

to time

institute, which numbershall

determine

the total number of authorized employees for the

not exceed 70 employees (full time equivalentl

excluding members of the

working groups and members of the ICOC who shall not be considered institute employeesand
excludinq up to 15 additional institute employees (full time equivalent) to support the development of
policies and proqrams to help make treatments

and cures arisinq from institute-funded

research

available and affordable for Californians. The cap on employees shall not apply to employees funded
throuqh
sources other than bond proceeds or the General Fund. The ICOC shall select a chairperson, vice
chairperson
following

and president
functions

(A) The chairperson's
evaluations

apply

who
to

primary

and approvals

shall

exercise

all of the powers

delegated

to

them by the ICOC. The

the chairperson, vice chairperson and president:
responsibilities

of scientific

are to manage

and medical

working

the
group

ICOC agenda
grants,

and workflow

loans,

facilities,

including

all

and standards
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evaluations,
optimize

and to supervise
the institute's

Legislature,
optimize

the

bond

United

all financial

reports

financing

States

plans

Congress,

leverage

matchinq or supplemental
institutions'

all annual

and public

and funding

the California

opportunities

for the

cashflow

health

for intellectual

requirements;

plan;

to interface

care system,

institute,

funds throuqh collaborations

and to lead negotiations

accountability

includinq

with

the

without

limitation

nations,

agreements,

public;

to

qeneratinq

territories,

policies,

and

California

and the California

with other states,

property

to manage

or

and contract

terms.

The Chairperson shall also serve as a member of the Treatments and Cures Accessibility and Affordability
Workinq

Group,

and Medical

the Scientific

Research

Medical

Research

support

the

Funding

the

highest

to serve

scientific

supporting

all working

standards

as well

recommendations,
hire,
the

group

requirements
and support

the

implementation

direct,

and manage

institute;

to manage

compliance

of all grant

recipients;

performance
any other

contracts

the staff

pertaining

(2) Each member

of the

out those

in the United

groups;

as to direct

to develop

of all decisions
institute;

with

institute

ICOC except,

on these

the institute

the

budgets

and execute

the chairperson,

of the

and
are to

absence.
institute;

to recruit

on its working
in the process

on grants,

loans,

and acting

on those

and general

and regulations

or research

of the

and participate

of evaluating

to develop

all rules

and to manage

to the

to serve

Scientific

responsibilities

Executive

recommendations

ICOC process

and the

in the Chairperson's

as the Chief

ICOC staff

Group

of the Scientific

primary

duties

States

to direct

the

of the

Working
member

The Vice Chairperson's

are to serve

talent

on its working

Standards

and as an ex officio

and to carry

responsibilities

and medical

the institute

Group

Group.

in all duties

primary

Accountability

Working

Working

Chairperson

(B) The president's

and Medical

Facilities

matters

facilities,

of the

and cost control

and

ICOC; to
programs

ICOC, including

all intellectual

groups;
of

of

the

property

agreements

and

it funds.

vice chairperson,

and

the members

appointed pursuant to paraqraphs (3), (4), (5), and (6) of subdivision (a) of Section 125290.20

who shall

be compensated pursuant to paraqraph

(3), shall receive a per diem of one hundred dollars (SIOO) per

day (adjusted

for each day actually

duties,

for cost of living)

plus reasonable

member's
(3)

annually

and necessary

travel

and other

spent

expenses

in the discharge

incurred

in the

of the

member's

performance

of the

duties.

The ICOC shall establish daily consulting

rates

and expense

reimbursement

standards

for the

members of all of its working groups, includinq the members of the ICOC appointed pursuant to
paraqraphs (3), (4), (5), and (6) of subdivision (a) of Section 125290.20.
include time spent in preparation
and shall include compensation
membeYs participation
(4) Notwithstanding
chairperson,

and scientific,
California

Section

subdivision
relocation

5EC. 14.

staff

medical,

system

of the

Government

and president
institute

technical,

(a) of Section

Section

and expense reimbursement

19825

of the

and the

expense

in, institute, workinq qroup, and ICOC meetinqs
for careqivers when necessary to facilitate

a

in a meetinq as a result of the membeYs medical condition.

vice chairperson,

and administrative

for, and participation

The daily consultinq rate shall

within

the

125290.20,

academic
and travel

the

officers,

range

and administrative

nonprofit

Code,

and other

of compensation

staff

of medical

and research
expense

ICOC shall set compensation
and for the scientific,

institutions

reimbursement

for the

medical,

levels for executive

schools

within

described

the

technical,
officers

University

in paragraph

rates

and movinq

amended

as follows:

of
(2) of

and

limits.

125290.50

of the

Health

and Safety

Code

is hereby
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125290.50.

Scientific

and Medical

Working

Groups

- General.

(a) The institute shall have, and there is hereby established
working

groups

(1) Scientific

and Medical

Research

(2) Scientific

and Medical

Accountability

(3) Scientific

and Medical

Research

Funding

Working

Group

Standards

Facilities

Working

Working

group

members"
expires
later,

ICOC, within
members"

terms

two

a-rA

Group.

Workinq Group.

of scientific and medical working group members shall be made by a majority vote of

of the

working

Group.

Members

lAppointments
a quorum

separate scientific and medical

Group.

(4) Treatments and Cures Accessibility and Affordability
(b) Working

f3y7

as follows:

will

years

shall

be staggered

later,

and one-third

30 days of the

terms

so that

one-third

of the

election

be six years
one-third

shall

that,

after

of the initial
the first

of the members

of the members

members

and appointment

except

shall

be elected

be elected

for a term

shall

terms,

be elected

for a term

that

ICOC members.

six-year

expires

that

for a term

expires

six years

The

the

four

later.

that
years

Subsequent

terms are for six years. Working group members may serve a maximum of two consecutive termsL
provided that the ICOC may, by a two-thirds
members

to serve

more

(2) Appointments

than

two

vote of a quorum, reappoint non-ICOC

consecutive

workinq qroup

terms.

of members of the Treatments and Cures Accessibility and Affordability

Workinq Group

shall be made by a maiority vote of a quorum of the ICOC, within 90 days of the effective date of the
Initiative

addinq

this paraqraph.

The workinq

qroup

members'

terms

shall

be six years,

and members

may serve a maximum of two consecutive terms, provided that the ICOC may, by a two-thirds
quorum,

reappoint

(3) The ICOC may

non-ICOC
appoint

expertise for a particular

workinq

ad

qroup

hoc votinq

members

members

to serve

to each

more

workinq

than
qroup

two

consecutive

as necessary

vote of a

terms.

to obtain

expert review session, not to exceed three members for any one expert review

session.

(c) Working

Group

Meetings

Each scicntific

and medical

working

be designated

as its annual

meeting,

(d) Working

Group

Recommendations

Recommendations

of each

group

shall

except
to the

hold

at least four

as otherwise

meetings

determined

per year,

one of which

shall

by the institute.

ICOC

the working groups

may

be forwarded

to the

ICOC only

by a vote

of

a majority of a quorum of the members of each panel for that working group. If 35 percent of the
members of any working group panel award scores in the fundinq ranqe, a minority recommendr:ition
report, includinq o summary of the strenqths and weaknesses of the application and a rebuttal to the
maiority recommendation, shall may be submitted to the ICOC. The ICOC shall consider the
recommendations of the working groups in making its decisions on applications
for research
and facility
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grants

and loan

group

shall

review

working

regulatory

to ICOC rules,

procedures,

group

(3) Because

adopt

conflict

committees

ofinterest

and practices

of the

rules,

National

appoint

the working

an ethics

groups

officer

based

Institutes

of the working

groups

shall

purposes

of the

Reform

Act (Title

Sections

Political
1090

from

are purely

members

Contract

and policies

and proqrams.

for that

working

Each working

group.

on standards

of Health,

applicable

to govern

the

to members

of

participation

of non-ICOC

members.

(2) The ICOC shall

Code)

standards

of Interest

The ICOC shall

scientific

and in adopting

recommend

(e) Conflict

(l)

awards

and 19990

among

advisory

the staff

and have

not be considered

no final
officials,

with

Section

Code,

institute.

decisionmaking

public

9 (commencing

of the Government

of the

and Sections

employees,
81000)

of the

10516

authority,
or consultants

for

Government

and 10517

of the

Public

Code.

(f) Working

Group

All records

Records

of the working

ICOC for approval
working

groups

shall
shall

groups

1 of Part I of Division

Section

6250)

of Chapter

Section

125290.55.

125290.55

Scientific

to the

not be subject

Chapter

SEC. 15.

submitted

be subject

to the

3 of Title

and Medical

Health

of the working

Records

provisions

2 of the

3.5 of Division

of the

as part

Public

Act.

of Article

Government

groups"

Except

9 (commencing
Code,

or Article

7 of Title 1 of the Government

and Safety

Accountability

Code

Standards

recommendations

as provided

is hereby

Working

to the

in this subdivision,
with

the

Section

11120)

1 (commencing

with

of

Code.

amended

as follows:

Group.

(a) Membership

The Scientific

and Medical

Accountability

Standards

Working

Group

shall

have 19 members

(1) Five ICOC members from the 10 groups that focus on disease-specific areas described

as follows:

in paragraphs

(3), (4), and (5) of subdivision (a) of Section 125290.20 or from the members appointed pursuant to
pamqraph (6) ofsubdivision (a) ofSection 125290.20.
(2) Nine

scientists

and clinicians

nationally

recognized

in the field

of pluripotent

and progenitor

cell

research.

(3) Four

medical

(4) The Chairperson

ethicists.

of the

ICOC.

(b) Functions

The Scientific

and Medical

Accountability

Standards

Working

Group

shall

have the following

functions:
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(1) To recommend

to the ICOC scientific,

(2) To recommend
trials

to the ICOC standards

and therapy

procedures

delivery

to patients,

for obtaining

treatment

medical,

of human

materials

subjects

Section 125290.35,

for all medical,

including,
research

compliance

others,

and clinical
with

patient

privacy

of the standards

and financial

standards

consistent

with

to the ICOC modification

standards.

socioeconomic,

among

and cells for research

in medical

and to ensure

(3) To recommend

and ethical

aspects

of clinical

for safe and ethical

efforts

for the appropriate

paragraph

(2) of subdivision

(b) of

laws.

described

in paragraphs

(1) and (2) as

needed.

(4) To mal<e recommendations
with the standards

to the ICOC on the oversight

described

in paragraphs

(5) To advise the ICOC, the Scientific
and Medical

Research

Facilities

research

to ensure

compliance

(1) and (2).

and Medical

Working

of funded

Group,

Research

Funding

on an ongoing

Working

Group,

basis, on relevant

and the Scientific

ethical

and regulatory

issues.

SEC. 16.

Section 125290.60

125290.60.

Scientific

of the Health

and Medical

and Safety

Code is hereby

Research

Funding

Working

Funding

Working

Group

amended

to read as follows:

Group.

(a) Membership
The Scientific

and Medical

(1) Seven ICOC members

Research
from

the -IG)12 disease advocacy

shall have at least 23 members

group

members

described

as follows:

in paragraphs

(3),

(4), and (5) of subdivision (a) of Section 125290.20 or the members described in paraqraph (6) of
subdivision (a) ofSection 125290.20.
(2) At least 15 scientists
opportunities,

nationally

recognized

in the field of stem cell research

15 of whom shall be desiqnated

(3) The Chairperson

to serve on each expert

review

or other

vital research

pr:inel.

of the ICOC.

(b) Functions
The Scientific

and Medical

(1) Recommend
funding

Research

to the ICOC interim

applications

and for awarding

Funding

and final criteria,
research

(2) Recommend

to the ICOC standards

(3) Recommend

to the ICOC any modifications

paragraphs

(4) Review grant

trial,

grants

for the scientific

Group

shall perform

standards,

the following

and requirements

functions:

for considering

and loans.
and medical

of the criteria,

oversight

standards,

of awards.

and requirements

described

in

(1) and (2) above as needed.
and loan applications

the ICOC and make recommendations
clinical

Working

and therapy

delivery

based on the criteria,

requirements,

to the ICOC for the award

grants

of research,

and standards
therapy

adopted

development,

by
,mA

and loans.
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(5) Conduct

expert

compliance

with

the terms

peer

of the

review

award,

r:ind progress
and report

oversight

to the

reviews

of grantees

to ensure

ICOC any recommendations

for subsequent

action.
(6) Recommend
applicable

to the

ICOC standards

requirements.

authorize

Such standards

the Scientific

and Medical

any recommendations
(7) Recommend

for action

its first

(c) Recommendations
Award

for the evaluation

grant

shall

Research

to the

awards

of grantees

mandate

periodic

Funding

recommendations

shall

record

of the

within

be based

60 days of the

upon

of achievement

for

innovativeness

(3) In order
shall

unlikely

to, receive

realizing

that

be placed

research.

issuance

a competitive

in the

areas

institute

other

potential

with

all

and shall

a grantee

and forward

of the interim

standards.

evaluation

as follows:

of pluripotent

stem

cell and progenitor

to be a Vital Rcscarch OpportunityL

cell

or in other

for achieving

results,

the

significant

importance

research,

or clinical

of the research

objectives,

research.

funding

does

pluripotent

or sufficient

regard,

the

such significant

proposed

on funding

timely

In this

proposal,

of the

to ensure

priority

the

research

the timetable

and the

by grantees

to audit

comply

opportunities.

(2) The quality
results,

Group

they

ICOC.

biology and medicing unltss the rcrcarch is dtttrmincd
research

reporting

Working

that

for Awards

(1) A demonstrated

vital

to ensure

stem

federal

research

not duplicate

or supplant

cell and progenitor

funding,

funded

by the

funding,

cell research

unencumbered

categories

existing

that

by limitations
National

a high
cannot,

or is

would

impede

of Health

shall

that

Institutes

not be funded by the institute, unless such research fundinq is not timely or sufficient.
(4) Notwithstanding paragraph (3), other scientific and medical research and technologies and/or any
stem
the

cell research
institute

proposal

not actually

if at least two-thirds

funded

of a quorum

by the institute
of the

members

under
of the

paragraph
Scientific

(3) may be funded
and Medical

by

Research

Funding Working Group recommend to the ICOC,or if a maiority of a quorum of the members of the
ICOC determine,

that

SEC. 17.

125290.70.5

Section

such a research

125290.70.5. Appropriation

is added

proposal
to the

is a Vital
Health

P,cscarch

and Safety

Opportunity
Code

to read

vital

research

opportunity.

as follows:

and Allocation of Fundinq.

(a) Monies in the California Stem Cell Research and Cures Fund shall be allocated as follows:
(1) (A) No less than ninety-five and one half percent (95.5%) of the proceeds of the bonds authorized
pursuant to Section 125291.110, net of bond proceeds allocated to purposes described in paraqraphs (4)
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and (5) ofsubdivision
in this

(a) of Section 125291.100,

shall be used for qrants and qrant oversiqht

C7Sprovided

chapter.

(B) Not less than 98 percent (98%) of the proceeds of bonds used for qrants shall be used for research,
therapy development,

and therapy delivery qrants, with no more than the followinq amounts-as

stipulated below - to be committed
addinq this subparaqraph,

durinq the first ten years followinq the effective date of the Initiative

with each yeaYs fundinq commitments

seven years, except that any such funds that are not committed

to be advanced over a period of one to

may be carried over to one or more

followinq years. The maximum amount of research fundinq to be allocated annually is as follows: Year 1,
11%; Year 2, 11%; Years 3 throuqh 10, 9%; and Year Il
accomplish the qoals ofSection 125290.75,

and each year thereafter, 6% cumulatively.

may be used for research consultinq in support of access to, and the r:iffordability of, treatments
cures arisinq from institute-funded

and

research and therapy development and delivery, as determined by the

Governinq Board of the institute based on the recommendations
Accessibility and Affordability

of the Treatments and Cures

Workinq Group and the President.

(C) Not more than three percent (3%) of the proceeds of bonds authorized by Section 125291.110
used by the institute for research and research facilities implementation
development,

administration

To

up to two percent (2%) of the amount available for qrants

and oversiqht of the qrant-makinq

may be

costs, includinq the

process.

(2) (A) Not more than three and one half percent (3.5%) of the proceeds of the bonds authorized
pursuant to Section 125291.110

shall be used for the costs of qeneral administration

of the Institute.

(B) Not more than one percent (1%) of the proceeds of the bonds authorized pursuant to Section
125291.110

may be used by the institute to pay for the costs of up to 15 full time employees over ten to

15 or more years, includinq but not limited to administrative
tmvel reimbursement,

support, facilities costs, salary, benefits,

and meetinq costs, to support the work of the institute to develop policies and

proqrams to help Californians obtain access to human clinical trials, therapies, mitiqatinq
and cures arisinq from institute-funded
such human clinical trials, treatments,

treatments,

research and to promote the accessibility and affordability

of

and cures for Californians.

(3) In any sinqle year any new research fundinq to any sinqle qrantee [or any proqram year is limited to
no more than one percent (1%) of the total bonds authorized pursuant to Section 125291.110.
limitation

shall be considered separately for each new proposal without aqqreqatinq

approvals that may fund research activities. This requirement

shall be determinative,

This

any prior year
unless 65 percent

of a quorum of the ICOC approves a hiqher limit for that qrantee.
(4) Up to one and one half percent (1.5%) of the proceeds of the bonds authorized pursuant to Section
125291.110,

net of costs described in paraqraphs (2), (4) and (5) ofsubdivision

(a) ofSection 125291.100

shall be allocated for qrants to build, equip, or fund operations of Community Care Centers of Excellence
and up to one half o7 one percent (0.5%) shall be allocated to build or equip Shared Labs, which are
intended to be operational

in the first five years 7ollowinq the effective date of the Initiative addinq this

Section. Fundinq received by a qrantee from an institute award for construction shall be subiect to
prevailinq

waqe

laws.

(5) The institute shall limit indirect costs to no more than 25 percent (25%) of a research award,
excludinq amounts included in a facilities awr:ird, except that the indirect cost limitation

may be
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increased by that amount by which the qrantee provides matchinq funds in excess of 20 percent (20%) of
the qrant

amount.

(b) The institute's

fundinq schedule is desiqned to create a positive tax revenue stream for the state of

California durinq the first five calendar years followinq the voters' approval of the initiative

addinq this

section, without drawinq funds from the state qeneral fund for principal and interest payments for those
first five calendar years.
(c) The institute shall allocate at least 5L5 billion of the proceeds of the bonds authorized pursuant to
Section 125291.110

to make qrr:ints for research, therapy development,

and thempy delivery involvinq

diseases and conditions of the brain and central nervous system, includinq but not limited to AlzheimeYs
disease,

Parkinson's

disease,

stroke,

dementia,

epilepsy,

schizophrenia,

depression,

traumatic

iniury, brain cancer, and autism, and for qrant oversiqht and qeneral administration
with such qrants and loans, subject to the limits in subparaqraph
of this Section and in subparaqraph

brain

costs associated

(C) of paraqraph (1) of subdivision (a)

(A) of paraqraph (2) of subdivision (a) of this Section.

(d) The allocation of the proceeds of bonds authorized pursuant to Section 125291.30 shall continue to
be qoverned

by Section

SEC. 18.

Section

(a) "Act"

means

(commencing

125291.15

the

with

Section

(b) "Board"

or "institute"
with

pursuant

means

(d) "Fund"

means

Health

Stem

Code

and Cures

of Part 5 of Division

the California

(b) of Section

the California

Stem

(a) of Section

the California

and Safety

Cell Research

125290.10)

means

subdivision

to subdivision

70.

of the

California

accordance

(c) "Committee"

125290.

Institute

is hereby

Bond

amended

to read

Actconstituting

as follows:

Chapter

3

106.

for

Regenerative

Medicine

designated

in

125291.40.

Cell Research

and Cures

Finance

Committee

created

125291.40.

Stem

Cell Research

and Cures

Fund created

pursuant

to Section

125291.25.

(e) "Interim

debt" means any interim loans pursuant to subdivision (b) of Section 125290.70,

Sections 125291.60 and 125291.65,

bond anticipation

and

notes or commercial paper notes issued to make

deposits into the fund and which will be paid from the proceeds of bonds issued pursuant to this article.
SEC. 19.

Section

125291.35.

125291.35

of the

Health

The bonds authorized by

and Safety

Code

is hereby

amended

to read

as follows:

Artide 2 shall be prepared, executed, issued, sold, paid,

and redeemed as provided in the State General Obligation Bond Law (Chapter 4 (commencing with
Section 16720) of Part 3 of Division 4 of Title 2 of the Government

Code), and all of the provisions of that
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law, as amended from time to time, except subdivisions (a) and (b) of Section 16727 apply to the bonds
and to this
SEC. 20.

article

and are hereby

Section

125291.60

incorporated

of the

Health

in this article

and Safety

Code

as though

set forth

is hereby

amended

in full in this
to read

article.

as follows:

For the purpose of carryinq out Article 2, The the Director of Finance may authorize the

125291.60.
withdrawal

from

the General

bonds

have

been

that

Fund

authorized

of an amount

or amounts,

by the committee,

not to exceed

to be sold for the

the amount

purpose

of the

of carrying

unsold

out this

article excludinq any refundinq bonds authorized pursuant to section 125291. 75, less any amount loaned
pursuant to section 125291.65

and not yet repaid, and any amount withdrawn

pursuant

to this Section

and not

deposited

in the fund.

Any money

made

equal

interest

that

received

from

Fund,

plus an amount

Investment

Account,

yet returned

to the

from

money

to the General

available

under
the

Fund.

this section

money

from the General Fund

Any amount

would

shall
have

the sale of bonds

withdrawn

be returned

earned

for the

in the

purpose

shall

be

to the General
Pooled

Money

of carrying

out this

article.

SEC. 21.

Section

125291.65.
Pooled

125291.65

The institute

Money

of the

Health

may request

Investment

Account

and Safety

the

Pooled

Code

Money

in accordance

with

is hereby

amended

Investment
Section

Board

16312

to read

to make

as follows:

a loan from

of the Government

the

Code for the

purposes of carrying out

Artide 2, excludinq any refundinq bonds authorized pursuant to

section

loaned

125291.

withdrawn
Fund.

75, less any amount

to this section

from the General Fund pursuant to Section 125291.60

The amount

by resolution,
execute

pursuant

of the

has authorized

any documents

Any amounts

request

loaned

shall

to be sold for the

required
shall

not exceed

by the

be deposited

the amount

purpose

Pooled

Money

in the fund

and not yet repaid,

and any amount

and not yet returned to the General
of the

of carrying

unsold

bonds

out this

article.

Investment

Board

to be allocated

by the

to obtain
institute

that

the

committee,

The institute

shall

and repay

the

in accordance

loan.
with

this article.

SEC. 22.

Section

125291.70.
bonds

125291.70

All money

sold shall

of the

deposited

be reserved

Health

and Safety

in the fund

in the fund

that

and shall

Code

is hereby

is derived

from

be available

amended

premium

for transfer

to read

and accrued
to the General

as follows:

interest

on

Fund as a

credit to expenditures for bond interest, except that amounts derived from premium may be reserved
and used to pay costs of issuance prior to any transfer to the General Fund.
SEC. 23.

Section

125291.75.

The bonds

6 (commencing
which

is a part

issuance
to refund

125291.75

of the

with

of the

issued

Section

16780)

of the

State

described

originally

and Safety

and sold pursuant

bonds

any bonds

Health

General

of Chapter
Obligation

in this
issued

article

under

refunded with the proceeds of refundinq

Code

to Artide

is hereby

2 may

be refunded

4 of Part 3 of Division
Bond
includes

this article

Law.
the

amended

Approval
approval

or any previously

as follows:

in accordance

4 of Title
by the
of the

to read

2 of the Government
voters

issuance

issued

with

of the

state

of any bonds

refunding

Article
Code,
for

the

issued

bonds.

bonds as authorized by this section may be leqally defeased to

27

Amended

11.18.19

the extent permitted

by law in the mr:inner and to the extent set forth in the resolution, as amended from

time to time, r:iuthorizinq that refunded bond.
SEC. 24.
read

Article

2.5 is added

to Chapter

3 of Part

5 of Division

106

to the

Health

and Safety

Code

to

as follows:

ARTICLE2.5. California Stem Cell Research, Treatments, and Cures Bond Act of 2020
125291.90.

This artide shall be known, and may be cited, as the California Stem Cell Research,

Trer:itments, and Cures Bond Act of 2020.
125291.95.
(a)"Act"

As used in Artide 2.5, the followinq

terms have the followinq meaninq:

means the California Stem Cell Research and Cures Act constitutinq

Chapter 3 (commencinq

with Section 125290.10) of Part 5 of Division 106, as amended by the California Stem Cell Research,
Treatments, and Cures Initiative of 2020.
(b) "Board" or"Institute"

means the California Institute for Reqenerative Medicine desiqnated in

accordance with subdivision (b) of Section 125291.120.
(c) "Committee"

means the California Stem Cell Research and Cures Finance Committee created pursuant

to subdivision (a) of Section 125291.40

and desiqnated in accordance with subdivision (a) of Section

125291.120.

(d)"Fund"
pursuant

means the California Stem Cel) Research, Treatments, and Cures Fund of 2020 created
to Section

125291.105.

(e)"Interim

debt"

means

any interim

loans

pursuant

to Sections

125291.140

and 125291.145,

bond

anticipation

notes or commercial paper notes issued to make deposits into the fund and which will be

paid from the proceeds of bonds issued pursuant to this article.
125291.100. (a) Notwithstandinq Section 13340 of the Government Code or any other provision of law,
moneys in the fund are appropriated without reqard to fiscal years to the institute for the purpose of (1)
makinq qrants or loans to fund research and construct facilities for research, all as described in and
pursuant to Section 125290. 70.5, (2) payinq qeneral administrative costs of the institute (not to exceed
three and one half percent (3.5%) in accordance with subparaqraph (A) of paraqraph (2) of subdivision
(a) of Section 125290. 70.5), (3) payinq the annual administration costs of any interim debt or bonds after
December 31 of the fifth full calendar year after this Section takes effect, (4) payinq the costs of issuinq
interim debt, payinq the annual administration costs of the interim debt until and includinq December 31
of the fifth full calendar year after this Section takes effect, and payinq interest on interim debt, if such
interim debt is incurred or issued on or prior to December 31 of the fifth full calendar year after this
Section takes effect, and (5) payinq the costs of issuinq bonds, payinq the annual administration costs of
the bonds until and includinq December 31 of the fifth full calendar year after this Section takes effect,
and payinq interest on bonds that accrues on or prior to December 31 of the fifth full calendar year after
this Section takes effect (except that such limitation does not apply to premium and accrued interest as
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provided in Section 125291.150). In addition, moneys in the fund or other proceeds of the sale of bonds
authorized by this article may be used to pay principal of, redemption price (includinq accrued interest),
or premium on any interim debt issued prior to the initial issuance of bonds authorized by this article.
Moneys deposited in the Fund from the proceeds of interim debt may be used to pay qeneral
administrative costs of the Institute without reqard to the three and one half percent (3.5%) limit set
forth in (ii) above, so lonq as such three and one half percent (3.5%) limit is wtisfied

for each issue of

bonds.

(b) Repayment of principal and interest on any loans made by the Institute pursur:int to this article shall
be deposited in the fund and used for the purposes of Section 125290. 70.5, includinq the Institute's
administrative
125291.105.

costs, or for payinq continuinq costs of the annual administration

of outstandinq

bonds.

The proceeds of interim debt and bonds issued and sold pursuant to this article shall be

deposited in the State Treasury to the credit of the California Stem Cell Research and Cures Fund of 2020,
which is hereby created in the State Treasury, except to the extent that proceeds of the issuance of bonds
are used directly

125291.110.

to repay

interim

debt.

Bonds in the total amount of five billion and five hundred million dollars (55,500,000,000),

not includinq the amount of any refundinq bonds issued in accordance with Section 125291.155,

or as

much thereof as is necessary, may be issued and sold to provide a fund to be used for carryinq out the
purposes expressed in this article and to be used and sold for carryinq out the purposes of Section
and to reimburse
the General Obliqation Bond Expense Revolvinq Fund pursuant
to Section

125291.100

16724.5 of the Government Code. The bonds, when sold, shall be and shall constitute a valid and bindinq
obliqation o[ the State of California, and the full faith and credit of the State of California is hereby
pledqed for the punctual payment of both the principal of, and interest on, the bonds as the principal and
interest

become

125291.115.
redeemed

due and payable.

The bonds
as provided

authorized
in the State

by this article
General

shall

be prepared,

Obliqation

Bond

executed,

Law (Chapter

issued,

sold,

4 (commencinq

paid,
with

and
Section

16720) of Part 3 of Division 4 of Title 2 of the Government Codel and all of the provisions of that law, as
amended from time to time, except subdivisions (a) and (b) of Section 16727 apply to the bonds and to
this article and are hereby incorporated
125291.120.

in this article as thouqh set forth in full in this article.

(a) Solely for the purpose of authorizinq

the issuance and sale, pursur:int to the State

General Obliqation Bond Law, of the bonds and interim debt authorized by the article, the California
Stem

Cell Research

desiqnated

as "the

and Cures Finance
committee"

Committee,

as that

term

established

is used in the State

pursuant
General

to Section
Obliqation

125291.40,
Bond

is hereby

Law.

(b) For purposes of the State General Obliqation Bond Law, the California Institute for Reqenerative
Medicine

125291.125.

Governinq

Board

is desiqnated

(a) The committee

shall

the"board."

determine

whether

or not it is necessary

or desirable

to issue bonds

authorized pursuant to this article in order to carry out the actions specified in this article and, if so, the
amountofbondstobeissuedandsold.
TheTreasurershallusereasonableeffortstosellbondswith
pricinq at par or better and to pay the issuance costs out of premium if reasonably achievable and in the
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best interests of the state, at the TreasureYs discretion. Successive issues of bonds may be authorized
and sold to carry out those actions proqressively, and it is not necessary that all of the bonds authorized
to be issued

be sold

r:it any one time.

The bonds

may bear

interest,

which

is includable

in qross

income

for federal income tax purposes if the committee determines that such treatment is necessary in order to
provide funds for the purposes of the act. The costs of each bond issue sold on or after the sixty-first
month after this article takes effect shall be at the discretion of the Treasurer, and may be amortized
over or up to o forty-year period.
(b) The total amount of the bonds r:iuthorized by Section 125291.110

that mr:iy be issued in any calendar

year, commencinq in 2021, shall not exceed a cumulative averaqe of five hundred and forty million
dollars (';540,000,000). If less than this amount of bonds is issued in any year, the remaininq permitted
amount

may be carried

over

to one or more

subsequent

years.

Pursuant

to Section

125291.140,

the

Director of Finance may, in the DirectoYs discretion, authorize a loan from the General Fund to the
Institute on or after the effective date of this article.
(c) Until December 31 of the fifth full calendar year after this section becomes effective, all interest on
any interim debt or bonds issued under this article will be paid from proceeds from the sale of
such interim debt or bonds in accordance with the obiective of this Initiative of avoidinq any debt service
payments by the General Fund (both principal and interest) durinq the initial period of basic research and
therapy development followinq the effective date of this section.
125291.130.

There

shall

be collected

each

year and in the same

manner

and at the same

time

C7S other

state revenue is collected, in addition to the ordinary revenues of the state, a sum in an amount required
to pay the principal of, and interest on, the bonds becominq due each year. It is the duty of all officers
charqed by law with any duty in reqard to the collection of the revenue to do and perform each and
every

act that

125291.135.

is necessary

to collect

Notwithstandinq

that

additional

sum.

Section 13340 of the Government Code, there is hereby appropriated

from the General Fund in the State Treasury, for the purposes of this article, an amount that will equal
the total of the followinq:
(a) The sum annually necessary to pay the principal of, and interest on, bonds issued and sold pursuant
to this article,

as the principal

and interest

become

due and payable.

(b) The sum necessary to carry out Section 125291.140
125291.140.
withdrawal

appropriated

without reqard to fiscal years.

For purposes of carryinq out this article, the Director of Finance may authorize the
from the General Fund of an amount or amounts, not to exceed the amount of the unsold

bonds thr:it have been authorized by the committee,

to be sold for the purpose of carryinq out this r:irtide,

excludinq any refundinq bonds authorized pursuant to section 125291.155,

less any amount loaned

pursuant to section 125291.145

and not yet repaid, and any amount withdrawn

pursuant

yet returned

deposited
Fund,

to this section

and not

in the Fund. Any money

plus an amount

equal

made

to the interest

to the General

available
that

under

Fund.

Any amount

this section

the money

would

shall

have

from the General Fund
withdrawn

be returned

earned

shall

be

to the General

in the Pooled

Money

Investment Account, from money received from the sr:ile of bonds for the purpose of carryinq out this
r:irtide.
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125291.145.

The institute may request the Pooled Money Investment Board to make a loan from the

Pooled Money Investment Account in accordance with Section 16312 of the Government Code for the
purposes of carryinq out this article. The amount of the loan shall not exceed the amount of the unsold
bonds that the committee, by resolution, has authorized to be sold for the purpose of carryinq out this
article excludinq any refundinq bonds authorized pursuant to section 125291.155, less any amount
loaned pursuant to this section and not yet repaid, and any amount withdrawn from the General Fund
pursuant

to Section

any documents
amounts

125291.140

required

loaned

shall

and not yet returned

by the Pooled
be deposited

Money

to the Generr:if

Investment

Board

in the Fund to be allocated

Fund.

to obtain

The institute
and repay

by the institute

shall

execute

the loan.

in accordance

Any
with

this

article.

125291.150. All money deposited in the Fund thm is derived from premium and accrued interest on
bonds sold shr:ill be reserved in the Fund and shall be available for transfer to the General Fund as a
credit to expenditures for bond interest, except the amounts derived from premium may be reserved and
used to pay costs of issuance prior to any transfer to the General Fund.
125291.155. ThebondsissuedandsoldpursuanttothisarticlemayberefundedinaccordancewithArticle
6 (commencinq with Section 16780) of Chapter 4 of Part 3 of Division 4 of Title 2 of the Government Code,
which is a part of the State General Obliqation Bond Law. Approvaj by the voters of the state for the
issuance of the bonds described in this article includes the approval of the issuance of any bonds issued to
refund any bonds oriqinally issued under this article or any previously issued refundinq bonds. Any bond
refunded with the proceeds of refundinq bonds as authorized by this section may be leqally defeased to
the extent permitted by law in the manner and to the extent set forth in the resolution, as amended from
time to time, authorizinq that refunded bond.
125291.160. Notwithstandinq any provision of this article or the State General Objiqation Bond Law, if
the Treasurer sells bonds pursuant to this article that include a bond counsel opinion to the effect that
the interest on the bonds is excluded from qross income for federal tr:ix purposes, under desiqnated
conditions, the Treasurer may maintain separate accounts for the investment of bond proceeds and the
investment earninqs on those proceeds. The Treasurer may use or direct the use of those proceeds or
earninqs to pay any rebate, penalty, or other payment required under federal law or to take any other
action with respect to the investment and use of bond proceeds required or desirable under federal law
to maintain the tax-exempt status of those bonds and to obtain any other advantaqe under federal law
on behalf of the funds of this state.
125291.165.

The proceeds from the sale of bonds authorized by this article are not "proceeds of taxes"

r:isthat term is used in Artide Xlll B of the California Constitution and the disbursement of these proceeds
is not subiect to the limitations imposed by that article.
SEC. 25. Section

125292.10.

125292.10

of the

Health

and Safety

Code

is hereby

amended

to read

as follows:

Definitions.
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125292.10.

As used in this Chapter

have the following

(a) "Act"
with

means the California

Section 125290.10)

(b) "Adult
that

and in Article

Stem Cell Research

Constitution,

and Cures Act constituting

of Part 5 of Division 106 of the Health

stem cell" means an undifferentiated

can renew

XXXV of the California

the following

terms

meanings:

itself and may, with

certain

cell found
limitations,

Chapter

3 (commencing

and Safety Code.

in a differentiated

differentiate

tissue

in an adult

organism

to yield all the specialized

cell types

of the tissue from which it originated, such as a cell which is committed to make all of the functional

cells

of the tissue or orqan in which it resides and reqenerates but which is itself undifferentiated.
(c)"Basic

research"

plasticity,

cellular

means

the investiqation

differentiation

of basic mechanisms

and other

vital research

underlyinq

stem cell bioloqy,

cellular

opportunities.

4,e4
fgj)"Capitalized interest" means interest funded by bond proceeds.
M

{gl "Committee"

pursuant
4,e4"{fl

means the California

to subdivision
Constitutional

Stem Cell Research

and Cures Finance

Committee

created

(a) of Section 125291.40.
officers"

means the Governor,

Lieutenant

Governor,

Treasurer,

and Controller

of

California.
(q) "Early

development"

translated

to enable

(4 {j3l "Facilities"

bonds"

date, including

% {il "Fund"

discovery

of promisinq

use and ultimately

means buildings,

j,4d {j) "Floating-rate
maturity

means

broad

building

means

means the California

patient

leases, or capital

bonds which

commercial

new stem cell-based

improve

technoloqies

that

could be

care.
equipment.

do not bear a fixed

rate of interest

until their

final

paper notes.
Stem Cell Research

and Disease Cures Fund created

pursuant

to

Section 125291.25.

Jp fjl "Grant" means a grant, loan, or guarantee.
Jffl fil "Grantee"
institutions

%

means a recipient

shall be considered

of a grant from

as separate

"Human reproductive cloning"

being by transferring
removed

the nucleus

for the purpose

from

the institute.

and individual

means the practice
a human

ofimplanting

All University

grantee

of creating

product

in a uterus

Jp fz3l "Indirect costs" mean the recipient's costs in the administration,
and general

support

costs will be utilized
Group to create

costs for implementing

for recipients

which

and Medical

on this definition,

with

grantee

accounting,

a human
has been

a pregnancy.
general

overhead,

NIH definitions

ofindirect

Research

modifications

to create

the nucleus

to initiate

a grant or loan of the institute.

as one of the bases by the Scientific

a guideline

or attempting

cell into an egg cell from

the resulting

of California

institutions.

Standards
to reflect

Working
guidance

by

the ICOC and this act.
J,% {3) "Institute"

means the California

Institute

for Regenerative

Medicine.
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W {p) "Interim
regulations"
Chapter

standards" means temporary standards that perform the same function

under

the Administrative

4-& 3.5, Sections

comment

on the

11340

permanent

Procedure

et seq.)

Act (Government

except

regulations,

that

remain

in order

in force

Code,

to provide

Title

2, Division

greater

for 270 days rather

as "emergency
3, Part 1,

opportunity

than 180

for public

days.

W [gJ "Life science commercial entity" means a firm or organization, headquartered in California, whose
product
development
and commercialization.
business model includes biomedical or biotechnology
W fzJ"Medical

ethicist" means an individual with advanced training in ethics who holds a Ph.D., MA, or

equivalent training in the bioloqical sciences or the field of clinical medicine or clinical ethics and who
and writing
on ethical issues related to medicine,
spends or has spent substantial time (1) researching
and (2) administering
institutional

review

4,e44
{51 "Pluripotent
differentiate

ethical safeguards during the clinical trial process,

cells" means cells that are capable of self-renewal,

into

multiple

nuclear

transfer

or from

donated

under

appropriate

treatments

would

the ability

adult

cell types.

surplus

Pluripotent

products

informed

otherwise

% {j) "Progenitor

of in vitro

consent

be intended

and give

stem

through

service

on

procedures.

and have broad potential to

cells may be derived

fertilization

treatments

These

to be discarded

cells" means multipotent

to divide

% {yl "Quorum"

particularly

boards.

excess

if not utilized

from

when

somatic

such

cells from

in vitro

for medical

are

fertilization

research.

or precursor cells that are partially differentiated

rise to differentiated

cell

products

but retain

cells.

means at least 65 percent of the members who are eligible to vote.

% {yl "Research donor" means a human who donates biological materials for research purposes after
full disclosure

and consent.

% {ffl "Research funding"
research,

includinq

translational

includes interdisciplinary

but not limited

research,

therapy

to

'

development,

of applications;

research,

early

of

the reimbursement

development,

'

treatments

of patient-qualified

costs for

and their careqivers pursuant to paraqraph (4) of subdivision (b) of Section

the operations

125290.35;

cell discovery

and the development

through clinical trials, includinq without limitation
research participants

scientific and medical funding for
stem

of the Workinq Groups,

includinq

the costs associated

with

the costs of advisory qroups and consultants established or retained

the expert
to evaluate

advise the Governinq Board, the Workinq Groups, and awardees; and research conferences.
facility's

grant

orloan

development,

as direct
with

for the facility.

and communication
research

federal

provided

to house

all elements

of the

research,

funding

and state

In all cases, operating

services,
costs.

governments

utilities,

costs

maintenance,

Legal costs of the
and research

Institute
institutions;

of the facility,
janitorial,

incurred

to implement

including,

and security,

in order

to negotiate
standards

shall be considered

M [fl "Research participant"
in clinical

direct

research

funding

lease

rate

but not limited
shall

be included
standards

or regulations;

resolve disputes; and/or to carry out all other actions necessary to defend and/or advance
mission

Whena

therapy

and/or clinical trials, research funding shall include an allowance for a market

of reimbursement
to, library

has not been

review
and

the

to

Institute's

costs.

means a human enrolled with full disclosure and consent, and participating

trials.
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(y) "Research
alonq

J

proqram"

the research

means research

continuum

proiects

that are desiqned

and that are conducted

General

of the Institute

are greater

the same ultimate

by the same or overlappinq

ffl "Revenue positive" means all state tax revenues

and facilities

to advance

generated

than the debt service

directly

investiqators.

and indirectly

on the state

qoal

by the research

bonds actually

paid by the

Fund in the same year.

W {ggl "Stem
differentiate

cells"

mean nonspecialized

into more

(ab) "Stem

mature

cell discovery

cells that

cells with

research"

have the capacity

specialized

to divide

in culture

and to

functions.

means basic research,

early development,

and the discovery,

evaluation, or improvement of tools and technoloqies in the fields of stem cell and qenetic research
other

vital research

M

'Vital research opportunity Rtscarch

technologies,
and/or

includinq

any stem

science

Scientific

but not limited

cell research

of Section 125290.60
medical

which

not actually
provides

as determined

and Medical

Opportunity"

to qenetics,
funded

superior

Funding

Working

under

research

reproductive

cloning

paragraph

and

(3) of subdivision

opportunity,

(c)

vital to advance

of the members

and recommended

shall not be a vital research

research

and aqinq as a patholoqy,

vote of a quorum

Group

and medical

medicine,

by the institute

a substantially

by at least a two-thirds

Research

means scientific

personalized

of the

as such by that working

group to the ICOC,or as determined by the vote of a maiority of a quorum
Human

and

opportunities.

of members

of the ICOC.

opportunity.

SEC. 26. Amendment.

The provisions
approved
voters

of this Initiative,

by the voters.

by a statute

Legislature
the intent

SEC. 27.

of this Initiative

is passed by a vote of seventy
by the Governor,

provided

of the grant and loan programs

may not be amended

may be amended
percent

after

created

the measure

its approval

of the members

that such amendments

before

is

by the

of each house of the

are consistent

with

and further

by this Initiative.

Severability.

If any provision
any person

of this Initiative,

or circumstances,

applications

of provisions,

the provisions

those

to the entities

that this Initiative

or any invalid

SEC. 28.

Conflicting

development

from

be severed

have been enacted
application

exempt

in full force

from

regardless

the applicability

of whether

or

and to this end

unreviewable

judgment

of the Initiative

and the Initiative

the Initiative.

or part to

provisions,

and effect,

were to find in a final,

should

formerly

of any provision

the remaining

but shall remain
If a court

or activities

exceptions

or activities

would

included

(a) In the event

are severable.

or the application

held to be invalid,

shall not be affected,

of one or more entities

unconstitutional,

applicable

or part of this Initiative,

is for any reason

of this Initiative

that the exclusion
Initiative

the bond provisions,

The provisions

that

and signed

except

should

It is the intent

any invalid

provision

renders

the

be made
of the voters
had been

had been made.

Initiatives.

that this Initiative

shall appear

and another

measure

on the same statewide

ballot,

addressing

medical

the provisions

research

of the other

or therapy
measure

or

34

Amended

11.18.19

measures

shall

greater

be deemed

number

of affirmative

Initiative

shall

(b) If this

Initiative

approved

to conflict

prevail

is later

SEC. 29.

Standing.

invalid,

Notwithstanding

any other

constitutionality

of this

agency

of this State

constitutionality
is in state

or federal

and/or the Supreme
shall

be a charge

have the

Court

of the

United

appropriated

to intervene

States.

with

and given

in any court

it, the

The reasonable

receives

provisions

conflicting

full force

measure

and effect.

state

challenging

the

whether

by the Supreme

of Justice,

which

the

governmental

Court

fees and costs of defending

Department

of this

ballot

fail to defend

any other
action

a

shall be null and void.

its constitutionality,
review

Initiative

and the conflicting

or any of its officials

of defending

California

election,

by the voters,

or on discretionary

to the

this

by law by any other

be self-executing

purpose

that

or measures

shall

authority

on appeal,

on funds

but superseded

its approval

court,

to conflict

measure

of law, if the State,

for the

trial

deemed

other

at the same

following

Initiative

In the event

of votes

Initiative

provision

Initiative,

shall

of this

number

this

measure.

a measure

and the

by the voters

by a greater

held

this

than

entirety,

is approved

by voters

measure

votes

in their

with

shall

such action
of California
the action
be satisfied

promptly.

SEC. 30.

Liberal

This Initiative

Construction.

shall

be liberally

construed

to effectuate

its purposes.
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December 2, 2019

Hon. Xavier Becerra
Attorney General
1300 I Street, 17th Floor
Sacrame nto , California 9 5814

RECEIVED
DECO2 2D19
1NITIATJVE ('

Attention:

Ms. Anabel Renteria
Initiative Coordinator

ATTORNEY

r

.

-~U RDiNATOR
GENtRAL 'S OFFI CE

Dear Attorney General Becerra:
Pursuant to Elections Code Section 9005 , we have reviewed the proposed statutory initiative
(A.G. File No. 19-0022, Amendment #1) that would authori ze $5.5 billion in general obligation
bonds for stem cell research and enact various changes to the California Institut e for
Regenerative Medicine (CIRM).

Background
Researchers Use Stem Cells to Study and Treat Various Diseases. Stem cells are certain
types of cells that exist within humans. Researchers are interested in these types of cells for their
potential to regenerate lost cells , tissues, and organs. The field of medicine that uses stem cells
and other techniques for this purpose is known as "regenerative medicine. " One well-kno wn
example of a regenerative medicin e procedure is a bone marrow transplant. Under this
procedure , the bone marrow of a donor (which contains stem cells) is transferred to another
patient to replenish lost blood cells , typically due to certain types of cancer. Scientists are
researching the use of stem cells to treat many other diseases and health condit ions.
Voters Established State Stem Cell Research Program . In 2004, voters approved
Proposition 71, whic h gave researchers in California a constitutional right to conduct stem cell
research . The measure also created a new state program to fund stem cell research projects ,
research faci lities, and other related activities. In tandem , it created a new entity, CIRM, to
admini ster the program. The measure also established a CIRM oversight ·structure, which
includes (1) a 29-member governing board responsible for making funding decisions and
adopt ing relevant policie s, (2) three working groups responsible for advising the governing
board, and (3) a five-member committee responsible for providing independent oversight over
CIRM ' s finances.
Voters Approved $3 Billion in General Obligation Bonds for Stem Cell Program. To fund
stem cell grants and CIRM 's operations, the measure authori zed the state to sell general
obligation bonds. State genera l obligation bonds are a form of borrowing. The state sells the
bonds to investors , and the proceeds of these sales provide funding to CIRM . The state sells the
Legislative Analyst's Office
California Legislature
Gabriel Petek. Legislative Analyst
925 L Street. Suite 1000, Sacraml.'.nlo. CA 958 1-1
(916) 445-4656
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bonds when CIRM needs the funds (typically once a round of grant awardees has been selected).
Once the bonds are sold to investors, the state begins repaying the investors with interest by
malcing annual payments over time. Proposition 71 did not specify the length of the repayment
period for each bond issuance, but the state tended to repay the bonds over ten years.
Proposition 71 bonds were taxable and a ten-year repayment period is common for these types of
bonds. (For taxable bonds, the interest that investors earn is not exempt from federal taxes.)
CIRM Has Spent Nearly All Available Funds. As Figure 1 shows, bonds issued under
Proposition 71 have comprised virtually all ofCIRM's funding, with a relatively small amount
of funding coming from investment income, private donations, and other sources. CIRM has
spent most of the available funding on grants, with smaller amounts spent on CIRM's operations
and bond costs (discussed later in this letter). As of October 2019, all but $132 million of
CIRM' s funding has been spent.· According to CIRM staff, the remaining funding will be used
primarily to oversee active grants.

Summary of CIRM Budget
CumulativeBudget Since 2004 (In Millions)
Funds
Authorizedbonds
Investmentincome
Private donations
Other
Total

Uses of Funds
Grants
CIRM operations
Bond interest payments
Bond issuance costs
Total

RemainingFunds

$3,000
28
9

6
$3,043
$2,652"
189

68
3
$2,911

$132

a Includes$269 millionIn grantfundsthathavebeencommitted
butnot
yet releasedto grantees.
CIRM= CaliforniaInstitute
forRegenerative
Medicine.

Grants Have Funded Several Different Purposes. As Figure 2 (on the next page) shows,
CIRM has awarded about 75 percent of grant funds for specific research projects, including
clinical trials. The remaining 25 percent of grant funds have supported research facility
construction and equipment, related activities (for example, establishing a network of
laboratories dedicated to implementing human clinical trials), and various education initiatives
(for example, research internships for undergraduate students). The University of California has
received the greatest amount of grant funding, followed by nonprofit universities and institutions
(such as Stanford University).
CIRM Is Reducing Staffing Levels. Under Proposition 71, CIRM could spend no more than
3 percent of bond proceeds on its general administrative costs and no more than 3 percent to

3
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administer grants. At full implementation, CIRM reports having over 50 full-time equivalent
staff. As it nears the end of its programmatic funding, it has reduced operations. Currently,
CIRM employs 35 full-time equivalent staff.

Summary of Stem Cell Grants
$2. 7 Billion in Grant Funding Since 2004

By Program

By Recipient

!.AO\
aRefers to lakinga findingfrom basloresearchand convertingIt Intoa treatmentthat oanbe testedIn a cllnlcallrlal.

CIRM Used a Small Share of Bond Proceeds for Interest Payments. Typically, the state
makes regular payments on general obligation bonds from the state General Fund. Proposition 71
required the state to take a somewhat different approach. For the first five years after receiving
voter approval, the measure required CIRM to repay interest using the bonds' proceeds.
According to CIRM, a total of about $70 million of bond proceeds were spent on interest costs
from 2004 through 2009. In 2010, the state began paying the remaining principal and interest
from the General Fund. Currently, the state is spending $327 million annually from the General
Fund to make debt payments on Proposition 71 bonds.
Small Amount of Funding Spent on Bond Issuance Costs. Typically, certain administrative
and legal costs are associated with a bond issuance. Proposition 71 specified that bond proceeds
were to cover these administrative costs. CIRM reports using $2.6 million in bond proceeds for
these costs.
Grant Recipients Have Contributed Matching Funds to Their Projects. Many of CIRM's
programs require a match from grant recipients. The amount of funding that applicants must
match varies by program. To cover their match, grants recipients can rely on a number of
different fund sources, including philanthropic donations, federal grants, and industry
contributions. Many recipients raise more funding than required. According to CIRM, grant
recipients report collecting a combined $4. 1 billion in matching funds since 2004.

Hon. Xavier Becerra
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Grantees Are Required to Share Invention-Related Income With the State. Some stem cell
research is expected to lead to new inventions, including new medical technology and
treatments. Proposition 71 established an expectation that grant recipients share a portion of the
income resulting from licensing or commercializing these inventions with the state. The state's
share of the income is deposited into the state General Fund (the state's main operating account),
which is available to support any state program. Over the years, CIRM's governing board has
developed specific revenue-sharing policies. Since 2004, grant recipients have contributed
$352,560 in total invention-related income to the state.
Proposal
Authorizes $5.5 Billion in Bonds for Stem Cell Activities. The proposed measure would
authorize new bonds to fund additional grants and CIRM operations. As Figure 3 (see next
page) shows, the measure limits the amount of funds CIRM can spend on its operations. In
addition, the measure sets aside a portion of bond funds for certain grant programs, such as
grants for research projects that are aimed at developing treatments and cures for diseases
affecting the brain and nervous system. For a few of these programs, CIRM's governing board
would be required to prioritize grant applications that offer matching funds and ensure grant
awardees are distributed across the state.
Establishes Certain Rules and Guidelines Relating to the Bonds. The measure would limit
the amount of bonds the state could sell each year, with the goal of spreading bond sales over at
least a ten-year period. For the first five years after the measure is enacted, bond proceeds would
cover any interest payments on the issued bonds. Beginning January 1, 2026, the state would pay
all remaining debt from the General Fund. The State Treasurer would decide the period over
which to repay the bonds, with a maximum repayment period of 40 years.
Makes Numerous Changes to CIRM. The measure would malce various changes to CIRM's
programs and governance structure. Figure 4 (see page 6) summarizes these changes. One
notable change would be to refocus some of CIRM' s efforts toward improving patient access to
stem cell treatments. Under the measure, CIRM would be allowed to hire up to 15 full-time
equivalent employees to research and develop ways to improve access to treatments. A new
working group of national experts would advise CIRM's governing board on ways to improve
access and affordability. Furthermore, the measure would require any revenue earned from
revenue-sharing agreements to be used to offset patient costs for regenerative medicine
treatments.
Fiscal Effects
Total Estimated State Costs of $7.8 Billion. For the purposes of estimating the cost of the
measure, we assume the bonds are sold over an initial ten-year period-the minimum period
required by the measure. We assume each bond is repaid over 15 years, resulting in a total
repayment period of25 years. Though the typical repayment period for taxable bonds is
ten years, we assume a somewhat longer period given the measure specifies that the Treasµrer
could decide to stretch repayments up to 40 years. Under these assumptions, we estimate the
measure would cost a total of$7.8 billion-$5.5 billion in principal and $2.3 billion in interest.
The average annual payment over the 25-year period would be $310 million. The costs would be
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higher or lower than our estimates depending on factors such as the interest rate and the period of
time over which the bonds are repaid.

Issuance cost

Determined by State Treasurer

Legal, underwriter, and other costs to
Issue the bond.

Interest payments

Determined by bond sales

Annual interest payments on any debt
issued before January 1, 2026.

[lr~lMl,oi~-=:.-~.--·--·-·

·=-=~~~~
-~---=-

--- -

General administration

Up to 3.5 percent

Human resources, finance,
information technology, and other
administrative staff at CIRM.

Grant oversight

Up to 3 percent

C\RM staff dedicated to oversight of
grant programs.

Access to treatments

Up to 1 percent

CIRM staff focused on improving
patient access to new stem cell
der\vecl_tli_era{)les_and
treatmrants.

Community Care Centers of
Excellence

Up to 1.5 percent

Start-up costs to establish new sites
that conduct human clinical trials.

Shared Labs Program

Up to 0.5 percent

Start-up costs to establish state·
funded facilities devoted to research
on human embryonic stem cells.

Research on therapies and
treatments for diseases affecting
the brain and nervous system

$1.5 bllllon

Research on Alzheimer's disease,
Parkinson's disease, stroke,
dementia, and many other related

-Grants

diseases.
Remaining grants

All remaining funds

Research programs, clinical trials of
new treatments, education pipeline
Initiatives, and other stem
cell-related programs.

a Amounts/shares
are calculatedafter bondcostshavebeencovered.
CIRM "" Californialnstltulefor RegenerativeMedicine.

Likely Low Hundreds of Millions in Interest Payments Paid by Bond Proceeds. Under the
measure, a portion of the $2.3 billion interest cost would be paid by the bond proceeds. The
portion of interest repaid from the bond proceeds would depend on the timing of when the state
begins issuing bonds and the interest rate at which the bonds are sold. Were the state to begin
issuing bonds shortly after approval of the measure, CIRM would likely make interest payments
totaling in the low hundreds of millions of dollars from bond proceeds by the end of 2025.
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Summary of Notable Proposed Programmatic and
Governance Changes
ProgrammaticChanges
• Would establish grant program to expand sites and facilities supporting
clinical human trials.
• Would establish grant program to support stem cell-related
apprenticeships, graduate fellowships, and other academic programs at
the California State University and the California Community Colleges.
• Would require the Callfornla Institute of Regenerative Medicine (CIRM)
to provide grants for new research facilities at California universities and
nonprofit institutions.
• Would require the state to use any Income earned from CIRM agreements
to Improve the affordability of stem cell treatments.

GovernanceChanges
• Would increase the number of Independent Citizens Oversight Committee
(ICOC) members from 29 to 35.
• Would create one new working group to advise ICOC on Improving access
to regenerative medicine treatments.
• Would create new advisory boards to advise CIRM on scientific and policy
matters.
• Would limit CIRM to 70 lull-time equivalent employees.
• Would authorize CIRM to hire up to an additional 15 full-time equivalent
employees, above the 70 employee limit, who would be dedicated to
improving access to stem cell-derived therapies and treatments.

Difficult to Estimate Amount of Invention-Related Income Likely to Be Generated. To the
extent CIRM funds new projects that result in licensed and commercialized products, the state
would receive a portion of the resulting revenue. The amount of revenue received for this
purpose is uncertain. Many times, research does not lead to an invention, but, in a few cases,
inventions do result and are lucrative. Also, a significant amount of time typically elapses from
an initial research project to commercializing an associated invention. To date, the state has
collected only a few hundred thousand dollars in invention-related income. Past revenue
collections, however, might not be a good indicator of future revenue for the reasons cited above.
Other Possible Fiscal Effects. The measure could result in numerous other indirect effects
on state and local governments. For example, to the extent the measure results in new treatments
that are more cost-effective than existing treatments, state and local governments could
experience savings in some programs such as Medi-Cal, the state's subsidized health care
program for low-income people. The magnitude of these and other indirect effects is unknown.
Summary of Fiscal Effects. This measure would have the following major, direct fiscal
effects:
•

State costs of$7.8 billion to pay off principal ($5.5 billion) and interest ($2.3 billion)
on the bonds. Associated average annual debt payments of about $310 million for
25 years. The costs could be higher or lower than these estimates depending on
factors such as the interest rate and the period oftime over which the bonds are
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repaid. The state General Fund would pay most of the costs, with a relatively small
amount of interest repaid by bond proceeds.
Sincerely,

c~

.h,S"Keely Martin Bos!
Director of Finance

